Posts With Tag Australian Securities Exchange

Explore Radiopharm Theranostics Limited's Feb 2025 Form 6-K, detailing director interests & securities changes. Key updates for investors.

Explore Mesoblast Limited's February 2025 financial report, including key announcements and insights from CEO Silviu Itescu. Stay informed on the company's latest developments.

Radiopharm Theranostics Limited's Form 6-K highlights Lantheus's A$8M investment, signaling growth potential. Key compliance details and strategic insights for investors.

Explore Immuron Limited's latest Form 6-K report detailing significant events, public notices, and regulatory compliance insights as of January 10, 2025.

Discover Immuron Limited's January 2025 Form 6-K report detailing its proposed securities issue. Key insights include ASX announcement and filing status. Stay informed!

Discover key insights from Mesoblast Limited's 6-K filing, including executive updates, annual report plans, and a recent ASX announcement. Essential for stakeholders!

Explore Mesoblast Limited's latest Form 6-K, detailing their ASX announcement and compliance with U.S. regulations as of December 20, 2024.

Explore Radiopharm Theranostics Limited's SEC Form 6-K dated Dec 19, 2024, detailing their securities application and compliance efforts for transparency in the U.S. market.

Explore Radiopharm Theranostics Limited's December 2024 Form 6-K report detailing significant announcements, including securities updates and director interests. Stay informed!